Zhang, Li

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,183

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yang, Y., Qu, S., Li, J., Hu, C., Xu, M., Li, W., Zhou, T., Shen, L., Wu, H., Lang, J., et al. (2021) · The Lancet Oncology

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 462

Patients with Exon 19 Deletion Were Associated with Longer Progression-Free Survival Compared to Those with L858R Mutation after First-Line EGFR-TKIs for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis

Zhang, Y., Sheng, J., Kang, S., Fang, W., Yan, Y., Hu, Z., Hong, S., Wu, X., Qin, T., Liang, W., et al. (2014) · PLoS ONE

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 175

A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial

Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 122

Sacituzumab tirumotecan versus docetaxel for previously treated EGFR -mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Fang, W., Li, X., Wang, Q., Meng, X., Zheng, W., Sun, L., Yao, W., Zhuang, W., Fan, Y., Zhuo, M., et al. (2025) · BMJ

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 51

Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial

HARMONi-A Study Investigators, Fang, W., Zhao, Y., Luo, Y., Yang, R., Huang, Y., He, Z., Zhao, H., Li, M., Li, K., et al. (2026) · JAMA

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 8

The Oncogenic EGFR–SHC1 Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer

Zheng, J., Zhao, S., Zhan, J., Zhuang, W., Chen, M., Jiang, W., Huang, Y., He, J., Hu, L., Pang, L., et al. (2026) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 2